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Abstract 
 
Background: Whilst antithrombotic therapy is recommended in people with atrial fibrillation (AF), 
little is known about the survival benefits of antithrombotic treatment in those with both high 
ischemic and bleeding risk scores. We aim to describe the distribution of these risk scores in those 
with a prior diagnosis of AF who have suffered stroke and to determine the net clinical benefit of 
antithrombotic treatment. 
 
Methods: We used regional stroke register data in the UK.  Patients with a prior diagnosis of AF and 
ischemic or hemorrhagic stroke patients were selected and their CHA2DS2-VASc  and 
HEMORR2HAGES scores retrospectively calculated. Logistic regression and Cox-proportional hazards 
models were constructed to determine the association between antithrombotic therapy prior to 
stroke and in hospital and long term mortality. 
 
Results: 1928 stroke patients (mean age 81.3 years (SD 8.5), 56.8 % women) with prior AF were 
included. Of these, 1761 (91.3%) suffered ischemic stroke. The most common phenotype (64%) was 
those with both high CHA2DS2-VASc  (≥2) and high HEMORR2HAGES score (≥4). In our fully adjusted 
model, patients on antithrombotic treatment with both high ischemic and bleeding risk had a 
significant reduction in odds of 31% for in hospital mortality (OR 0.69;95%CI 0.48,1.00: p=0.049)) 
and 17% relative risk reduction for long term mortality (HR 0.83;95%CI 0.71,0.97: p=0.02)).  
 
Conclusions: Our study suggests that antithrombotic treatment has a prognostic benefit following 
incident stroke in those with both high ischemic risk and high bleeding risk. This should be 
considered when choosing treatment options in this group of patients.  
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Introduction 
 
Management of modifiable risk factors is one of the key preventative strategies in stroke. Atrial 
fibrillation (AF) is one of the most common clinically significant arrhythmias with a prevalence of 
1.48% in the UK (1). It is associated with a 5 fold increase in the risk of stroke (2) and is responsible 
for up to 16% of ischemic strokes (3). Antithrombotic therapy can be initiated to reduce the risk of 
thrombotic events in people with AF but also carries the risk of hemorrhage.  This includes 
antiplatelet and anticoagulant medication. 
 
Risk stratification scores have been developed for estimation of future ischemic and hemorrhagic 
events and include CHA2DS2-VASc score for ischemic stroke and HEMORR2HAGES, ATRIA, and HAS-
BLED scores for bleeding risk (4). These scores form the basis of international guidelines for the 
management of patients with AF (5), (6).  
 
Whether guideline-based decision making leads to complete and appropriate antithrombotic 
coverage of AF patients and how best to guide decision making in those with both high ischemic 
and bleeding risk scores remains unclear. Prior studies have quantified the reduction in risk of 
ischemic stroke in those receiving antithrombotic treatment for AF (7) as well as a reduction in the 
severity of stroke and stroke mortality (8). However, little is known about the distribution of 
ischemic and haemorrhagic risk in patients that have suffered a cerebrovascular event, or the 
relationship of these scores and clinical outcomes in such patients, particularly how the balance 
between ischemic and haemorrhagic risk may impact on clinical outcomes.  
 
Using a regional prospective stroke registry from England, UK, we retrospectively calculated 
ischemic and bleeding risk scores in a disease cohort of stroke patients with prior AF and aimed to 
determine the distribution of ischemic and haemorrhagic risk, antithrombotic coverage and in 
hospital and long term stroke mortality for those with both high ischemic and high bleeding risk 
scores.  
 
  
  
Methods 
 
Population 
This was a disease cohort of patients consecutively admitted with stroke drawn from Norfolk and 
Norwich Stroke Register (NNSTR). The NNSTR is a prospective UK hospital-based register which 
included consecutive stroke patients and has a catchment of approximately 750,000 people. Data 
collection and the development of this database have been published previously (9). The disease 
cohort was followed up long term through record linkage. Record linkage with the UK NHS system 
ensures a robust ascertainment of co-morbidities and almost complete follow up data for vital 
status. Index stroke type was based on evidence clinical examination and neuroimaging (typically 
computerized tomography or magnetic resonance imaging). Patients admitted with confirmed 
stroke between January 2003 and June 2013 were included in this study. In total 9835 patients 
were admitted between January 2003 and June 2013.  
 
Ethics: 
The register received ethical approval from the Newcastle and Tyneside National Health Service 
(NHS) and Research Ethics Committee (12/NE/0170) as a research database. The protocol was 
approved by the Steering Committee of the Register. The study was conducted in accordance with 
the principles of the Declaration of Helsinki (1964) and later amendments.  
 
Measurement methods: 
Data collection methods of the register have been reported previously (9). In brief, patient 
characteristic data on age, sex, stroke type (ischemic / hemorrhagic), Oxfordshire Community 
Stroke Project (OCSP) classification were retrieved from the hospital’s patient administration 
database. Relevant biochemical and hematological measurements taken on hospital admission 
were collected by electronic record linkage. Information on pre-existing co-morbidities were 
identified from ICD-10 codes based on clinical findings and retrieved from the hospital’s 
administration database (diabetes (ICD E10-E14), heart failure (I50), atrial fibrillation (I48), coronary 
heart disease (I20-I25), chronic kidney disease (N18), hypertension (I10-I15), dyslipidemia (E78), 
peripheral vascular disease (I73.9), cancer (C00-C99), and MI (I21)). Co-morbidities diagnosed 
during and after hospital admission were identified in the same manner. Dead or alive status at 
discharge was recorded to capture in-hospital mortality. Date of death was recorded to capture 
  
long term mortality. Additional checks and linkage were performed against the hospital’s 
administration database to further validate the sample. Atrial fibrillation and atrial flutter were 
diagnosed on the basis of a 12 lead Electrocardiogram (ECG) and grouped together as both have an 
associated risk of stroke. There was no minimal follow up period and follow up for mortality was 
obtained by electronic record linkage. Patients were censored at 30/June/2013 and deaths updated 
until 12/12/2013. 
 
Statistical analysis 
Statistical analysis was performed using SPSS v. 24 (SPSS Inc., Chicago, IL, USA). For the sampled 
disease cohort of patients consecutively admitted with stroke the CHA2DS2-VASc scores (low risk <2, 
high risk ≥2) and HEMORR2HAGES scores (low risk <4, high risk ≥4) were retrospectively calculated 
from recorded clinical data, excluding stroke. HEMORR2HAGES score was chosen as the bleeding 
risk score due to data availability. HEMORR2HAGES scores were based on recorded age, sex, 
relevant co-morbidities, anemia, alcohol use and antiplatelet use. Prior bleeding events and genetic 
factors were not collected and not used in the score calculation.  CHA2DS2-VASc scores were based 
on age, sex and relevant co-morbidities. The sample was divided into those with a prior diagnosis of 
AF or atrial flutter that had ischemic stroke or hemorrhagic stroke at presentation. These groups 
were sub-divided into antithrombotic treatment or no treatment groups and groups based on their 
CHA2DS2-VASc  and HEMORR2HAGES score. Antithrombotic treatment was defined as any 
anticoagulant or antiplatelet use before the index stroke, as described previously (10).  
 
Descriptive statistics were presented for the overall sample and by stroke subtype and compared 
using one-way analysis of variance for means and Pearson’s Chi-squared test for categorical 
measures. A scatter plot of CHA2DS2-VASc  (high risk ≥2) and HEMORR2HAGES scores were derived 
and an R2 value calculated to show correlation between the two. Logistic and Cox-proportional 
hazards models were constructed to determine the association between antithrombotic therapy 
and in-hospital and long term mortality, respectively, in those with both high CHA2DS2-VASc  (high 
risk ≥2) and HEMORR2HAGES score (high risk ≥4). Adjusted analyses were undertaken to account 
for potential confounding factors such as age, sex, co-morbidities, stroke risk factors, stroke 
subtype and Oxford Community Stroke Project (OCSP) stroke classification. A variety of adjusted 
models were used to assess the effects of these potential confounding factors in a group sequential 
fashion. Model A adjusted for age and sex. Model B adjusted for variables in model A plus co-
  
morbidities diabetes, heart failure, coronary heart disease, chronic kidney disease, hypertension, 
MI and cancer. Model C adjusted for variables in model B plus stroke subtype and Oxford 
Community Stroke Project (OCSP) stroke classification.  
 
This was a registry study with retrospective analysis of prospectively collected data. A power 
calculation was not performed.   
  
  
Results 
 
Between 2003 – 2013, a total of 2582 patients with confirmed stroke and a previous diagnosis of AF 
were identified, and of these 654 (25.3%) were excluded due to missing data needed to calculate 
their ischemic and bleeding risk scores leaving 1928 patients (mean age 81.3 years (SD 8.5), 56.8 % 
women, 91.3% ischemic stroke). There was no minimal follow up period and follow up for mortality 
was obtained by electronic record linkage. The mean follow up (SD) was 2.06 (2.49) years, median 
1.06 years, total person years 3963.3. As shown in Table 4, the post exclusion sample was 
representative of the initial sample. The mean age, female predominance, stroke characteristics 
and co-morbidity proportions were similar before and after exclusion. 
 
Table 1 demonstrates sample characteristics by stroke subtype. There were significant differences 
(p=<0.05) between the groups in age, sex, OCSP classification (lacunar infarct (LACI), total anterior 
circulation infarcts (TACI), partial anterior circulation infarcts (PACI), posterior circulation infarcts 
(POCI)), CKD, antithrombotic therapy, CHA2DS2-VASc  and HEMORR2HAGES Scores. Other co-
morbidities were similar between the groups.   
 
Figure 1 shows the proportion of those with high and low ischaemic event and bleeding risk scores 
subdivided into treatment groups and stroke subtypes. A higher proportion of those on 
antithrombotic treatment who had an ischaemic stroke, had a high bleeding risk score (74.5%) 
compared to those not on antithrombotic treatment (43.6%). This was echoed in those who had 
suffered hemorrhagic stroke (65.4% vs 38.4%). 
 
Table 2 and Figure 1 show the proportion of ischemic stroke and hemorrhagic stroke patients who 
received treatment subdivided by their CHA2DS2-VASc and HEMORR2HAGES score. In the ischemic 
stroke group, 1091 (62.0%) of patients had a high CHA2DS2-VASc  and a high HEMORR2HAGES 
Scores. Of these, 779 (71.4%) received antithrombotic treatment.  A total of 627(35.6%) had a high 
CHA2DS2-VASc  and a low HEMORR2HAGES Scores, 248 (39.6%) were on antithrombotic treatment. 
There were no patients that had a low CHA2DS2-VASc and a high HEMORR2HAGES Score. A total of 
43 had a low CHA2DS2-VASc score and a low HEMORR2HAGES Score, of these 18 (41.9%) were on 
antithrombotic treatment. In the hemorrhagic stroke group, 145 patients had a high CHA2DS2-
VASc  and a high HEMORR2HAGES Score. Of these, 117 (80.7%) received antithrombotic treatment. 
  
A total of 100 had a high CHA2DS2-VASc  and a low HEMORR2HAGES Score, of these 56 (56%) were 
on antithrombotic treatment. There were no patients that had low CHA2DS2-VASc  score and a high 
HEMORR2HAGES Score. A total of 7 had a both low scores, of these 6 (85.7%) were on 
antithrombotic treatment. 
Table 3 shows logistic regression odds ratios (OR (95%CI)) for in hospital mortality and Cox 
regression hazard ratios (HR (95%CI)) for long term mortality for patients (n=1173) with both high 
CHA2DS2-VASc score and HEMORR2HAGES score on antithrombotic therapy compared to those not 
on antithrombotic therapy. In our fully adjusted model, patients on antithrombotic treatment with 
both high ischemic and bleeding risk had a significant reduction in odds of 31% for in hospital 
mortality (OR 0.69 (95%CI 0.48,1.00: p=0.049)) and a 17% relative risk reduction for long term 
mortality (95%CI 0.71, 0.97:p=0.02)). 
 
There is a positive correlation between CHA2DS2-VASc score and HEMORR2HAGES scores for all 1928 
men and women of the Norfolk and Norwich University Hospital Stroke Register with an R2 value of 
0.453. 
 
  
  
Discussion 
 
Our study has described the distribution of ischaemic stroke and bleeding risk within a large disease 
cohort of patients consecutively admitted with stroke who have suffered ischaemic or hemorrhagic 
stroke. Interestingly the most common phenotype (64%) described is those with both high 
ischaemic stroke and bleeding risk scores, which is perhaps not surprising given the overlap of risk 
factors within the scores. This clearly presents a challenge to clinicians weighing up the risks and 
benefits of antithrombotic treatment in this high-risk group of patients.  
 
Paradoxically, as shown in table 2, we observed that a larger proportion of patients with both a 
high ischaemic stroke and bleeding risk scores were treated with antithrombotic therapy than 
those with a high ischaemic stroke and low bleeding risk scores (71.4% vs 39.6%). This suggests a 
mismatch between clinical guidelines and clinical practice when considering antithrombotic 
treatment in a high risk group of patients. This may lead to an increased incidence of preventable 
stroke and greater morbidity and cost to healthcare systems globally.  
 
It is interesting to note that in our disease cohort who have suffered stroke those at high risk of 
both ischemic stroke and bleeding events who were treated with antithrombotic medication had a 
significant reduction in odds of in hospital mortality by 31% (OR 0.69 (95%CI 0.48 – 1.00 p=0.049)) 
and a relative risk reduction in long term mortality of 17% (HR 0.83 95%CI 0.71 – 0.97 p=0.02)). This 
suggests that even in those with a high bleeding risk antithrombotic treatment has a prognostic 
benefit following incident stroke and this should be taken into consideration when clinicians 
consider treatment in this group of patients. The treatment instituted after the specific stroke type 
is therefore assumed to be beneficial or will have similar impact on those who received the 
respective treatment. Therefore, they are not adjusted and regarded as process variable rather 
than a confounding factor in our study. 
 
In our study, over 40% of patients were not on antithrombotic treatment demonstrating low 
antithrombotic coverage within our disease cohort of patients consecutively admitted with stroke. 
This is in line with previous studies, which showed that between 30–50% of patients were 
undertreated (11). In the UK alone, it is estimated that if all those with AF were appropriately 
treated up to 7000 strokes would be prevented and 2000 lives saved each year (12).  
  
Net clinical benefit analysis has been previously carried out examining the risk and benefit of 
anticoagulation in AF patients. In general, these have shown that only those patients with a 
CHA2DS2-VASc score of 0 have a negative net clinical benefit and all other patients derive a positive 
benefit from antithrombotic treatment (13). In fact, those with a high bleeding risk score have been 
shown to derive a higher net clinical benefit from antithrombotic treatment as the risk reduction in 
ischemic stroke outweighs the relatively small increase in bleeding risk (14), (15).  
Barriers to initiation of antithrombotic therapy have been cited to include the risk of falls and 
concomitant medications (16). Additional composite risk scores may be useful in such 
circumstances, taking into account variables such as pre-stroke morbidity, anticoagulant profiles 
and frailty, in order to better risk stratify these patients. However, recent studies designing and 
validating composite risk scores have shown inconsistent results or lack convincing validation (17), 
(18). The development of such scores needs further investigation and validation in future studies. 
Whilst it is established that antithrombotic treatment improves survival following stroke (19), little 
is known about whether this benefit continues in those with a high risk of both ischemic stroke and 
bleeding events calculated based on their co-morbidities. In our fully adjusted model, accounting 
for age, sex, co-morbidities and stroke characteristics we have demonstrated a significant reduction 
in odds of in hospital mortality by 31% (OR 0.69 (95%CI 0.48 – 1.00 p=0.049)) and a relative risk 
reduction in long term mortality of 17% (HR 0.83 95%CI 0.71 – 0.97 p=0.02)) in this high risk group.  
Interestingly, the underutilization of antithrombotic medications in at risk populations has been 
demonstrated in a number of studies. A recent publication from a nationwide AF programme in 
Belgium (subjects screen between 2012 and 2014) showed sub-optimal antithrombotic therapy in 
those with CVD. Of those with prevalent CVD 1094 (72.3%) were not taking any antithrombotic 
medications.  This shows a low use of antithrombotic in those with prior CVD, despite international 
guidelines recommending this as secondary prevention in these patients. Those with prevalent CVD 
and AF (n=137) were either under- and over- treated; 32.5% were not taking any antithrombotic 
medication, 65.1% were taking both antiplatelet and anticoagulant medication and only 1.7% took 
an anticoagulant alone. This study also reiterated the importance of AF as a risk factor for CVD (OR 
3.28, 95CI 2.77 – 3.89, P <0.001) (20). In another study, of the 10,406 patients (81.9%) at high risk 
(CHA2DS2-VASc score ≥2) for thromboembolism in a large retrospective general practice derived 
cohort study in New Zealand (participants recruited in 2014), 60.5% were treated with 
anticoagulants, 24.1% received aspirin monotherapy and 15.4% were not treated with any 
  
antithrombotic medication. It also showed that 31.5% of patients at low risk (CHA2DS2-VASc <2) 
were treated with oral anticoagulants (21). These studies, in line with our study, highlights the 
disparity in antithrombotic treatment globally and the need for improved provision of 
antithrombotic treatment and adherence to treatment guidelines in those with AF and stroke. 
 
Our study has several strengths. We used a large disease cohort of patients consecutively admitted 
with stroke derived hospital based sample which consisted validated stroke events, which improves 
the generalisability of our findings. As a prospective study, with robust case ascertainment, we 
introduce less bias. We were able to control for a range of demographic, medical co-morbidities 
and stroke characteristics. 
 
There are some limitations worth discussing. Potential confounders were measured at baseline and 
it is possible that these may vary during the follow up period. While the HAS-BLED score performed 
best in predicting clinically relevant bleeding, with net reclassification improvement (10.3% 
compared with HEMORR(2)HAGES) and receiver-operating characteristic (ROC) analyses (c-indexes: 
0.60 vs.0.55 for HAS-BLED compared to HEMORR(2)AGES), we used the latter due to data 
availability. Nevertheless, both predict bleeding risk and those with a high HEMORR2HAGES score 
will most likely have a high HAS-BLED score (4). Prior bleeding events and genetic factors were not 
collected and not used in the score calculation for patient HEMORR2HAGES score. It is therefore 
possible that patient bleeding risk scores have been underestimated. As our disease cohort is 
comprised of those that survived stroke and did not die on transfer to hospital, there is a survival 
selection bias which may influence interpretation and generalisability of the survival benefits 
described. However they fit with other prognostic benefits described in the literature (19). It is clear 
that current practice has changed since data collection, in particular the advent of non-vitamin K 
antagonist oral anticoagulants, however this study aims to describe the risk scores in those with a 
prior diagnosis of AF who have suffered stroke and to determine the net clinical benefit of 
antithrombotic treatment in general terms to help guide future decision making. Events not 
requiring admission and certain non-medical general characteristics were not captured. However, 
the number of stokes occurring that do not lead to hospital admission will be low and therefore 
only likely to minimally attenuate the results. Whilst we were able to adjust for key potential 
confounders such as age, sex, co-morbidities and stroke risk factors, stroke subtype and OCSP 
  
stroke classification, due to data availability we were unable to adjust for biological confounders 
such as arterial blood pressure and serum lipid levels. We were unable to control for unknown or 
known confounders which were not adjusted for. An important missing confounder is the use of 
statins before index stroke. This data was unavailable in our dataset. However, we have accounted 
for major co-morbidities and stroke risk factors. 
 
Conclusion 
 
It is clear there is a need for improved provision of antithrombotic treatment and adherence to 
treatment guidelines to reduce the global burden of stroke. We have described the distribution of 
bleeding and ischaemic stroke risk in those with a prior diagnosis of atrial fibrillation who have 
suffered as well as demonstrating the prognostic benefit of antithrombotic treatment in those with 
both high ischemic stroke risk and bleeding risk scores. Clinicians should take this into account 
when discussing treatment options with patients with both high ischemic and hemorrhagic risk 
scores in order to make evidence based decisions in stroke prevention.  
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Table 1: Sample characteristics by stroke subtypes of 1928 men and women of the Norfolk and Norwich University Hospital Stroke Register. 
 
 All (n= 1928)* Before eclusion Ischemic stroke 
(n=1761) 
91.34% 
Hemorrhagic 
stroke 
(n=252) 
P* 
Age (SD) 81.3 (8.5) 81.54 (8.64) 81.4 (8.5) 80.1 (7.8) 0.029 
Sex (%) 
Men 
Women 
 
832 (43.2) 
1096 (56.8) 
 
910 (43.2) 
1192  ca 
Ischaemic stroke 
– 87.7 
 
 
746 (42.4) 
1015 (57.6) 
 
131 (52.0) 
121 (48.0) 
0.008 
OCSP classification (%) 
 LACS 
 PACS 
 POCS 
 TACS 
Other  
 Unknown 
 
320 (16.6) 
708 (36.7) 
263 (13.6) 
536 (27.8) 
24 (1.2) 
77 (4.0) 
  
316 (17.9) 
680 (38.6) 
217 (12.3) 
485 (27.5) 
14 (0.8) 
49 (2.8) 
 
16 (6.3) 
63 (25.0) 
64 (25.4) 
66 (26.2) 
12 (4.8) 
31 (12.3) 
<0.001 
Diabetes (%) 381 (19.8)  18.3 359 (20.4) 46 (18.3) 0.18 
  
Heart failure (%) 599 (31.1)  549 (31.2) 70 (27.8) 0.25 
Coronary heart disease (%) 814 (42.2)  749 (42.5) 104 (41.4) 0.32 
Chronic kidney disease (%) 851 (44.1)  789 (44.8) 92 (36.5) 0.002 
Hypertension (%) 1428 (74.1)  1310 (74.4) 188 (74.6) 0.67 
MI (%) 215 (11.2)  201 (11.4) 23 (9.1) 0.72 
Cancer (%) 373 (19.3) 16.1 347 (9.7) 46 (18.3) 0.22 
Antithrombotic therapy (%) 1175 (60.9)  1045 (59.3) 179 (71.0) <0.001 
CHA2DS2-VASc score (SD) 4.6 (1.7) 3.7 (SD1.81) 4.6 (1.7) 4.7 (1.7) 0.041 
HEMORR2HAGES score (SD) 4.0(1.6) 3.03 (SD 1.78) 4.0 (1.6) 3.9 (1.6) 0.035 
 
 
*n=85 had both ischemic and hemorrhagic  stroke 
 LACS = lacunar  syndrome, PACS =  Partial anterior circulation stroke, POCS = Posterior circulation syndrome, TACS = Total anterior 
circulation stroke 
 
 
 
  
  
  
Table 2: CHA2DS2-VASc  and HEMORR2HAGES score groups sub divided into antithrombotic treatment groups for Ischemic  and Hemorrhagic 
stroke groups. 
 
Ischemic stroke Low CHA2DS2-VASc  score (n=43) High CHA2DS2-VASc  score (n=1718) 
Treatment 
(n=18) 
No treatment 
(n=25) 
Treatment 
(n=1027) 
No treatment 
(n=691) 
High 
HEMORR2HAGES 
score (n=1091) 
0 (0%) 0 (0%) 779 (71.4%) 312 (28.6%) 
Low 
HEMORR2HAGES 
score (n=670) 
18 (41.9%) 25 (58.1%) 248 (39.6%) 379 (60.4%) 
Hemorrhagic stroke Low CHA2DS2-VASc  score (n=7) High CHA2DS2-VASc  score (n=245) 
 Treatment 
(n=6) 
No treatment 
(n=1) 
Treatment 
(n=173) 
No treatment 
(n=72) 
High 
HEMORR2HAGES 
score (n=145) 
0 (0%) 0 (0%) 117 (80.7%) 28 (19.3%) 
  
Low 
HEMORR2HAGES 
score (n=107) 
6 (85.7%) 1 (14.3%) 56 (56%) 44 (44%) 
 
 
  
  
Table 3: Logistic regression (OR (95%CI)) and cox regression hazard ratios (HR (95%CI)) for in hospital and long term mortality for those with 
both high CHA2DS2-VASc score and HEMORR2HAGES score on antithrombotic therapy compared to those not on antithrombotic therapy 
 
Logistic regression odds ratios for in hospital mortality 
Models  Events OR 95% CI  p-value  
A 312/1173 0.67 0.49 – 0.91 0.01 
B 312/1173 0.67 0.49 – 0.92 0.013 
C 312/1173 0.69 0.48 – 1.00 0.049 
Cox regression hazard ratios for long term mortality 
Models  Events HR  95% CI  p-value  
A 841/1173 0.81 0.69 – 0.95 0.007 
B 841/1173 0.80 0.68 – 0.93 0.005 
C 841/1173 0.83 0.71 – 0.97 0.02 
 
Model A – adjusted for age and sex. 
Model B – model A plus co-morbidities diabetes, heart failure, coronary heart disease, chronic kidney disease, hypertension, MI and cancer. 
Model C – model B plus stroke subtype and Oxford Community Stroke Project (OCSP) classification  
stroke classification. 
  
Table 4: Sample characteristics before and after exclusion of men and women of the Norfolk and Norwich University Hospital Stroke Register. 
 
 Before exclusion 
(n=9828) 
After exclusion (n=7503) P value 
Age (SD) 77.17 (11.99) 77.22 (11.77) 0.79 
Sex (%)                                 
Men 
Women 
 
4654 (47.4) 
5174 (52.6) 
 
3571 (47.6) 
3932 (52.4) 
 
0.75 
* OCSP classification (%)                      
LACS 
PACS 
POCS 
TACS 
2132 (21.7) 
3122 (31.8) 
1607 (16.4) 
1996 (20.3) 
 
1728 (23.0) 
2435 (32.5) 
1275 (17.0) 
1556 (20.7) 
 
0.04 
0.34 
0.26 
0.49 
Diabetes (%) 1534 (15.6) 1151 (15.3) 0.63 
Heart failure (%) 1325 (13.5) 998 (13.3) 0.73 
Coronary heart disease 
(%) 
2602 (26.5) 1977 (26.4) 0.85 
Hypertension (%) 5610 (57.1) 4252 (56.7) 0.59 
MI (%) 675 (6.9) 512 (6.8) 0.91 
Cancer (%) 1408 (14.3) 1046 (13.9) 0.47 
 
* LACS = lacunar  syndrome, PACS =  Partial anterior circulation stroke, POCS = Posterior circulation syndrome, TACS = Total anterior 
circulation stroke 
  
Figure 1: Proportion of those with high and low ischemic stroke and bleeding risk scores on antithrombotic treatment subdivided into stroke 
type for all 1928 men and women of the Norfolk and Norwich University Hospital Stroke Register. 
 
 
 
  
  
Figure 2: flow chart for criteria for selection of included sample 
 
 
 
 
7503 patients included 
9835 patients admitted 2003 - 
2013 
2332 Excluded 
 
Less than18 years old – 7 
 
Not followed up – 98 
 
Subarachnoid haemorrhage stroke – 156 
 
Date problem (date of death < date of 
admission)  - 8 
 
Patients had more than 1 Stroke – 798 
 
Missing antithrombotics on discharge  - 25 
 
Missing data to on length of stay, BAMFORD 
score, antiplatelets on admission, haemoglobin 
and creatinine – 1240 
 
1928 patients included in analysis 
with Atrial fibrillation and stroke 
